Dosing & Administration
This unit explains, for education only, the trial-validated dosing schedule for cagrilintide and CagriSema, so you can…
The trial schedule, and why you cannot buy it
This unit explains, for education only, the trial-validated dosing schedule for cagrilintide and CagriSema, so you can understand the published research. It is not a protocol or a recommendation, and cagrilintide is not legally available outside a Novo Nordisk clinical trial.
The honest throughline: the only real dosing information comes from the trials, the maintenance dose is reached by slow titration, and the "research peptide" cagrilintide sold online is unverified and not legally compoundable.
Key terms
The trial-validated schedule
The only legitimate dosing information for cagrilintide comes from the trials, and it is presented here as research context, not a prescription. Both the monotherapy and the CagriSema programs use a slow weekly up-titration to a defined maintenance dose.
Two points matter most. First, the regimen is a slow climb: roughly four months of dose escalation before reaching the 2.4 mg / 2.4 mg maintenance dose, then continued to the trial endpoint. Second, these figures describe a quality-controlled trial product delivered under medical supervision, not a number you can act on with an online vial.
This unit is education only and not medical advice. The trial regimen is research reference information, not a recommendation to use cagrilintide.